These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical approach to the inflammatory etiology of cardiovascular diseases. Ruscica M; Corsini A; Ferri N; Banach M; Sirtori CR Pharmacol Res; 2020 Sep; 159():104916. PubMed ID: 32445957 [TBL] [Abstract][Full Text] [Related]
3. Flavonols in the Prevention of Diabetes-induced Vascular Dysfunction. Leo CH; Woodman OL J Cardiovasc Pharmacol; 2015 Jun; 65(6):532-44. PubMed ID: 25387248 [TBL] [Abstract][Full Text] [Related]
4. "Anti-inflammatory" drugs and their effects on type 2 diabetes. Deans KA; Sattar N Diabetes Technol Ther; 2006 Feb; 8(1):18-27. PubMed ID: 16472047 [TBL] [Abstract][Full Text] [Related]
5. The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management. Yudkin JS J Diabetes Complications; 1996; 10(3):129-32. PubMed ID: 8807456 [No Abstract] [Full Text] [Related]
6. [Anti-diabetic therapy and cardiovascular risk]. Mannucci E G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):3S. PubMed ID: 25623544 [No Abstract] [Full Text] [Related]
7. Targeting inflammation in cardiovascular diseases. still a neglected field? Gómez-Guerrero C; Mallavia B; Egido J Cardiovasc Ther; 2012 Aug; 30(4):e189-97. PubMed ID: 21884009 [TBL] [Abstract][Full Text] [Related]
9. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. Schneider CA Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Ajjan RA; Grant PJ Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909 [TBL] [Abstract][Full Text] [Related]
11. Repurposing Metformin for Cardiovascular Disease. Rena G; Lang CC Circulation; 2018 Jan; 137(5):422-424. PubMed ID: 29378754 [No Abstract] [Full Text] [Related]
12. NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS. Grinspoon S Trans Am Clin Climatol Assoc; 2018; 129():140-154. PubMed ID: 30166708 [TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Fonseca VA Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042 [TBL] [Abstract][Full Text] [Related]
16. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Shen GX Can J Physiol Pharmacol; 2010 Mar; 88(3):241-8. PubMed ID: 20393589 [TBL] [Abstract][Full Text] [Related]
17. [Recommendations for cardiovascular assessment and risk reduction in diabetes--1999. Società Italiana di Diabetologia, the Diabetes and Atherosclerosis Study Group, Associazione Medici Diabetologi]. Ceriello A; Boemi M; Cucinotta D; De Feo P; Gensini GF; Lala A; Manzato E; Rivellese A; Ruotolo G; Vannuzzo D; Zavaroni I Cardiologia; 1999 Aug; 44(8):751-8. PubMed ID: 10476602 [No Abstract] [Full Text] [Related]
18. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Gerstein HC Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991 [TBL] [Abstract][Full Text] [Related]
19. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Raggi P; Genest J; Giles JT; Rayner KJ; Dwivedi G; Beanlands RS; Gupta M Atherosclerosis; 2018 Sep; 276():98-108. PubMed ID: 30055326 [TBL] [Abstract][Full Text] [Related]
20. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes]. Christiansen AL; Madsbad S Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]